Vabysmo

(faricimab) Roche

Composition^1,2:

• Injection: 120 mg/mL solution in a single-dose vial. 

Indications^1,2:

Vabysmo is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with:

• Neovascular (Wet) Age-Related Macular Degeneration (nAMD)
• Diabetic Macular Edema (DME)

Reference:

1. Drug Office. Department of Health, HKSAR. https://www.drugoffice.gov.hk/eps/drug/productDetail/en/pharmaceutical_trade/141191 (accessed on 27 Jan 2023)  2. Vabysmo (faricimab). US Prescribing Information 2022